喷司他丁

喷司他丁 基本信息
CAS号 53910-25-1 分子式 C11H16N4O4
分子量 268.26900 精确质量 　268.11700
PSA 　112.13000 LogP 　-1.41540
我要卖该产品 我要采购该产品

等价的CAS号：

53910-25-1,69196-04-9,80374-25-0,82264-17-3,82264-18-4
充值推广 查看更多供应商
目录
基本信息 制备方法与用途 物化性质 安全信息 合成路线 毒性 海关数据 结构与计算数据 上下游

基本信息 展开↓

CAS号：
53910-25-1
3D弹球模型：
立即前往扯扯看
分子式：
C11H16N4O4
分子量：
268.26900
中文名称：
喷司他丁
英文名称：
PENTOSTATIN
中文别名：
喷司他丁;
脱氧助间型霉素
英文别名：
PENTOSTATIN;
2'-deoxycoformycin;
Coforin;
Nipent;
2'-deoxy-D-coformycin;
ci-825;
PD-ADI;
Cl 825;
dcf;
yk-176;
Co-V;
deoxycoformycin;
Pentostatin
精确分子量/精确质量：
268.11700
极性分子表面积/PSA：
112.13000
油水分配系数/LogP：

LogP值指的是某物质在正辛醇/水两相体系中的分配系数的对数值，反映了物质在油水两相中的分配情况。其中、LogP值越大，说明该物质越亲油；反之，LogP值越小，则说明该物质越亲水。
InChI：
InChI=1/C11H16N4O4/c16-3-8-6(17)1-9(19-8)15-5-14-10-7(18)2-12-4-13-11(10)15/h4-9,16-18H,1-3H2,(H,12,13)/t6-,7+,8+,9?/m0/s1

生产制备方法及用途展开↓

制备方法

大规模生产以喷妥司汀的产生菌Streptomyces antibioticus进行浸入或深层培养来制备：一、发酵经选择的培养基植入灭过菌的水溶性营养液，在无菌条件下，于20～45℃(最好是33～40℃)，充气和搅拌培育，直至培养液中出现喷妥司汀。影响获得最大收率的时间的长短的因素是所用设备的类型和大小、搅拌的速度，充气的速度，微生物培养基和其它因素。在罐形发酵器中进行的大规模工业发酵，进行3～7d最大收率。也可采用较短的发酵时间，但收率较低。当在振荡瓶进行发酵时，所需的时间比用大容积的发酵罐的时间要长。在浸入培养时，微生物生长成分布于整个营养液的不连续的颗粒；而在表面培养时，是在营养液的表面形成连续的薄膜。由于微生物分布在整个营养液中，因而在采用发酵工业中使用的罐和缸进行微生物培养时，可以采用大容积的接种营养液。装有搅拌和充气装置的连续缸形发酵器特别适合大规模生产，但也可以使用其它发酵设备。在小量生产或制备用于大规模发酵的微生物培养基时，浸入培养可在小烧瓶中进行，可以采用适合的方法进行振荡或搅拌。在浸入培养时，培养液的充气和搅拌可用许多方式来完成。搅拌可用涡轮机、桨状搅拌器、叶轮推进器等其它机械搅拌设备，也可旋转或振荡发酵器本身，或用各种泵设备往营养液中注入空气或氧气而获得。充气可采用开口管、多孔管或带有分配器的管子来注入空气或氧气，或可将营养液喷、泼或溢到氧气气氛中。浸入培养外的另一选择方法是表面培养。此时使用2CM以下薄层的灭过菌的水溶性培养液，植入喷妥司汀的产生菌犛狋狉犲狆狋狅犿狔犲狊犪狀狋犻犫犻狅狋犻犮狌狊，在20～45℃和充氧下进行培育。和浸入培养相似可得产品。二、分离和提纯分离可采用压滤或离心分离。滤饼用水彻底洗涤，洗液和滤液合并后，用氢氧化钠、三乙胺或氢氧化铵等碱性水溶液调狆犎值至约9.2。减压浓缩至约剩1／10的体积。浓缩液冷至5℃，时间可在数小时或数天(依据体积大小而定)。析出的沉淀是9-(B-D-阿拉伯糖基呋喃糖基)腺嘌呤，可用硅藻土作助滤剂过除去。滤液用水稀释至其浓缩前的体积，然后用盐酸或硫酸等水溶性酸调狆犎值至约8.3。用活性炭或其它吸附剂(最好是Darco G-60)来吸附。吸附过程可分批进行，也可通过柱子连续进行。在批量方法中，把0.5％～10％，最好是约3％(W/V)的活性炭加入滤液，并搅拌1～3h。过滤，滤饼用水洗后，再用丙酮水溶液等量的丙酮和水洗脱。洗脱液浓缩至剩约1％～3％的体积。往浓缩液中加入甲醇，以获得80％甲醇溶液。过滤除去产生的沉淀，滤液浓缩以除去甲醇。浓缩液用5％丙酮的水溶液稀释至其2.5倍的体积，通过一活性炭柱子。该活性炭柱先用5％丙酮水溶液洗，再用10％丙酮水溶液洗。然后用25％丙酮水溶液洗脱。洗脱液减压浓缩后冻干。将干燥固体溶于小量水中，通过用水制备的装有Sephadex G-10的柱子进行渗滤。用水洗柱子，收集含产品的流出液，干燥，用甲醇水溶液结晶，可得喷司他丁。

合成制备方法

大规模生产以喷妥司汀的产生菌Streptomyces antibioticus进行浸入或深层培养来制备：
一、发酵
经选择的培养基植入灭过菌的水溶性营养液，在无菌条件下，于20～45℃(最好是33～40℃)，充气和搅拌培育，直至培养液中出现喷妥司汀。影响获得最大收率的时间的长短的因素是所用设备的类型和大小、搅拌的速度，充气的速度，微生物培养基和其它因素。在罐形发酵器中进行的大
规模工业发酵，进行3～7d最大收率。也可采用较短的发酵时间，但收率较低。当在振荡瓶进行发酵时，所需的时间比用大容积的发酵罐的时间要长。
在浸入培养时，微生物生长成分布于整个营养液的不连续的颗粒；而在表面培养时，是在营养液的表面形成连续的薄膜。由于微生物分布在整个营养液中，因而在采用发酵工业中使用的罐和缸进行微生物培养时，可以采用大容积的接种营养液。装有搅拌和充气装置的连续缸形发酵器特别适合大规模生产，但也可以使用其它发酵设备。在小量生产或制备用于大规模发酵的微生物培养基时，浸入培养可在小烧瓶中进行，可以采用适合的方法进行振荡或搅拌。在浸入培养时，培养液的充气和搅拌可用许多方式来完成。搅拌可用涡轮机、桨状搅拌器、叶轮推进器等其它机械搅拌设备，也可旋转或振荡发酵器本
身，或用各种泵设备往营养液中注入空气或氧气而获得。充气可采用开口管、多孔管或带有分配器的管子来注入空气或氧气，或可将营养液喷、泼或溢到氧气气氛中。浸入培养外的另一选择方法是表面培养。此时使用2CM以下薄层的灭过菌的水溶性培养液，植入喷妥司汀的产生菌犛狋狉犲狆狋狅犿狔犲狊犪狀狋犻犫犻狅狋犻犮狌狊，在20～45℃和充氧下进行培育。和浸入培养相似可得产品。
二、分离和提纯
分离可采用压滤或离心分离。滤饼用水彻底洗涤，洗液和滤液合并后，用氢氧化钠、三乙胺或氢氧化铵等碱性水溶液调狆犎值至约9.2。减压浓缩至约剩1／10的体积。浓缩液冷至5℃，时间可在数小时或数天(依据体积大小而定)。
析出的沉淀是9-(B-D-阿拉伯糖基呋喃糖基)腺嘌呤，可用硅藻土作助滤剂过除去。滤液用水稀释至其浓缩前的体积，然后用盐酸或硫酸等水溶性酸调狆犎值至约8.3。用活性炭或其它吸附剂(最好是Darco G-60)来吸附。吸附过程可分批进行，也可通过柱子连续进行。
在批量方法中，把0.5％～10％，最好是约3％(W/V)的活性炭加入滤液，并搅拌1～3h。过滤，滤饼用水洗后，再用丙酮水溶液等量的丙酮和水洗脱。洗脱液浓缩至剩约1％～3％的体积。往浓缩液中加入甲醇，以获得80％甲醇溶液。过滤除去产生的沉淀，滤液浓缩以除去甲醇。浓缩液用5％丙酮的水溶液稀释至其2.5倍的体积，通过一活性炭柱子。该活性炭柱先用5％丙酮水溶液洗，再用10％丙酮水溶
液洗。然后用25％丙酮水溶液洗脱。洗脱液减压浓缩后冻干。将干燥固体溶于小量水中，通过用水制备的装有Sephadex G-10的柱子进行渗滤。用水洗柱子，收集含产品的流出液，干燥，用甲醇水溶液结晶，可得喷司他丁。


用途简介

(为腺苷脱氨酶(ADA)抑制剂。用于α-干扰素治疗无效的毛细胞白血病。

用途

(为腺苷脱氨酶(ADA)抑制剂。用于α-干扰素治疗无效的毛细胞白血病。

物化性质展开↓

外观与性状：
白色晶体
密度：
1.81 g/cm3
熔点：
220-225ºC
沸点：
646ºC at 760 mmHg
闪点：
344.5ºC
折射率：
1.793
其它信息：

1.性状：从甲醇-水得白色结晶

2.熔点（ºC）：220～225

安全信息展开↓

海关代码：
2934999090

合成路线查看所有的合成路线

  • 69195-92-2

    2-氨基-1-(5-氨基-1H-咪唑-4-基)乙酮双盐酸盐

  • →

  • 53910-25-1

    喷司他丁

  • 52162-55-7

    3,5-Di-O-(p-toluyl)-2-deoxy-D-ribofuranosyl chloride

  • →

  • 53910-25-1

    喷司他丁

  • 69196-02-7

    3-(2-deoxy-3,5-di-O-p-toluoyl-α-D-erythro-pentofuranosyl)-6,7-dihydroimidazo[4,5-d][1,3]diazepin-8(3H)-one

  • →

  • 53910-25-1

    喷司他丁

毒理性展开↓

CHEMICAL IDENTIFICATION

RTECS NUMBER :
NI2931000
CHEMICAL NAME :
Imidazo(4,5-d)(1,3)diazepin-8-ol, 3-(2-deoxy-beta-D-pentofuranosyl)-3,6,7,8-tetrahydro- , (R)-
CAS REGISTRY NUMBER :
53910-25-1
LAST UPDATED :
199703
DATA ITEMS CITED :
23
MOLECULAR FORMULA :
C11-H16-N4-O4
MOLECULAR WEIGHT :
268.31

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Unreported
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
390 mg/kg/3D-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Blood - thrombocytopenia Blood - other hemolysis with or without anemia
REFERENCE :
IEDIEP Internal Medicine. (The Japanese Society of Internal Medicine, 34-3, 3-chome, Hongo, Bunkyo-ku, Tokyo 113, Japan) V.31- 1992- Volume(issue)/page/year: 34,593,1995
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
227 mg/kg
TOXIC EFFECTS :
Kidney, Ureter, Bladder - hematuria Nutritional and Gross Metabolic - body temperature decrease
REFERENCE :
KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 24,7888,1990
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
122 mg/kg
TOXIC EFFECTS :
Behavioral - altered sleep time (including change in righting reflex) Behavioral - somnolence (general depressed activity) Nutritional and Gross Metabolic - weight loss or decreased weight gain
REFERENCE :
NTIS** National Technical Information Service. (Springfield, VA 22161) Formerly U.S. Clearinghouse for Scientific & Technical Information. Volume(issue)/page/year: PB84-211424
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
360 mg/kg
TOXIC EFFECTS :
Sense Organs and Special Senses (Eye) - miosis (pupillary constriction) Gastrointestinal - changes in structure or function of salivary glands Gastrointestinal - nausea or vomiting
REFERENCE :
KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 24,7888,1990 ** OTHER MULTIPLE DOSE TOXICITY DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
650 mg/kg/26W-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Endocrine - other changes Blood - changes in bone marrow (not otherwise specified)
REFERENCE :
TOPADD Toxicologic Pathology. (c/o Dr. F.A. de la Iglesia, Warner-Lambert Co., Pharmaceutical Research Div., POB 1047, Ann Arbor, MI 48106) V.6(3/4)- 1978- Volume(issue)/page/year: 22,519,1994
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
80 mg/kg/4W-I
TOXIC EFFECTS :
Lungs, Thorax, or Respiration - changes in lung weight Endocrine - changes in spleen weight Nutritional and Gross Metabolic - weight loss or decreased weight gain
REFERENCE :
CCPHDZ Cancer Chemotherapy and Pharmacology. (Springer-Verlag New York, Inc., Service Center, 44 Hartz Way, Secaucus, NJ 07094) V.1- 1978- Volume(issue)/page/year: 5,83,1980
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
18200 ug/kg/26W-C
TOXIC EFFECTS :
Blood - other changes Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - phosphatases Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - transaminases
REFERENCE :
KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 25,4277,1991
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
28 mg/kg/4W-I
TOXIC EFFECTS :
Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol) Blood - changes in leukocyte (WBC) count Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - transaminases
REFERENCE :
KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 25,1271,1991
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
91 ug/kg/26W-C
TOXIC EFFECTS :
Blood - other changes Nutritional and Gross Metabolic - weight loss or decreased weight gain Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - transaminases
REFERENCE :
KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 25,4277,1991
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
14 mg/kg/4W-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - urine volume increased Kidney, Ureter, Bladder - other changes in urine composition Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol)
REFERENCE :
KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 25,1271,1991 ** REPRODUCTIVE DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
DOSE :
7500 ug/kg
SEX/DURATION :
female 6-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - musculoskeletal system
REFERENCE :
TJADAB Teratology, The International Journal of Abnormal Development. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1968- Volume(issue)/page/year: 44,325,1991
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
DOSE :
7500 ug/kg
SEX/DURATION :
female 6-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - sex ratio
REFERENCE :
TJADAB Teratology, The International Journal of Abnormal Development. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1968- Volume(issue)/page/year: 44,325,1991
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
500 ug/kg
SEX/DURATION :
female 10 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - blood and lymphatic systems (including spleen and marrow) Reproductive - Specific Developmental Abnormalities - immune and reticuloendothelial system
REFERENCE :
TJADAB Teratology, The International Journal of Abnormal Development. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1968- Volume(issue)/page/year: 25(2),36A,1982
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
5 mg/kg
SEX/DURATION :
female 8 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
REFERENCE :
TJADAB Teratology, The International Journal of Abnormal Development. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1968- Volume(issue)/page/year: 40,615,1989
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
1 mg/kg
SEX/DURATION :
female 7 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
REFERENCE :
TJADAB Teratology, The International Journal of Abnormal Development. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1968- Volume(issue)/page/year: 45,91,1992
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
5 mg/kg
SEX/DURATION :
female 7 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system
REFERENCE :
TJADAB Teratology, The International Journal of Abnormal Development. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1968- Volume(issue)/page/year: 47,17,1993
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
5 mg/kg
SEX/DURATION :
female 7 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - Central Nervous System
REFERENCE :
TJADAB Teratology, The International Journal of Abnormal Development. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1968- Volume(issue)/page/year: 47,17,1993
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
DOSE :
5 mg/kg
SEX/DURATION :
female 6-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
REFERENCE :
KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 25,3977,1991
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
DOSE :
8300 ug/kg
SEX/DURATION :
male 9 week(s) pre-mating female 2 week(s) pre-mating - 6 day(s) after conception
TOXIC EFFECTS :
Reproductive - Maternal Effects - other effects Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
REFERENCE :
KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 25,3965,1991
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
DOSE :
8300 ug/kg
SEX/DURATION :
male 9 week(s) pre-mating female 2 week(s) pre-mating - 6 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - musculoskeletal system
REFERENCE :
KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 25,3965,1991
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
DOSE :
28 ug/kg
SEX/DURATION :
female 15-21 day(s) after conception lactating female 21 day(s) post-birth
TOXIC EFFECTS :
Reproductive - Effects on Newborn - stillbirth Reproductive - Effects on Newborn - live birth index (measured after birth) Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive)
REFERENCE :
KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 25,4329,1991
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
DOSE :
28 ug/kg
SEX/DURATION :
female 15-21 day(s) after conception lactating female 21 day(s) post-birth
TOXIC EFFECTS :
Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4) Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) Reproductive - Effects on Newborn - physical
REFERENCE :
KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 25,4329,1991
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
DOSE :
1300 ug/kg
SEX/DURATION :
female 6-18 day(s) after conception
TOXIC EFFECTS :
Reproductive - Maternal Effects - other effects Reproductive - Fertility - abortion Reproductive - Specific Developmental Abnormalities - musculoskeletal system
REFERENCE :
KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 25,4319,1991

海关数据查看详细

中国海关编码：2934999090

概述：
2934999090. 其他杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%
申报要素：
品名, 成分含量, 用途
摘要/Summary：
2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

分子结构与计算化学数据展开↓

分子结构数据

1、  摩尔折射率：62.65

2、  摩尔体积（cm3/mol）：147.4

3、  等张比容（90.2K）：444.2

4、  表面张力（dyne/cm）：82.3

5、  极化率（10-24cm3）：24.83

上下游相关产品

上游产品

更多

  • 69195-91-1

    2-氨基-1-[5-氨基-1-(苯基甲基)-1H-咪唑-4-基]乙酮

  • 69195-97-7

    2-硝基-1-[5-硝基-1-(苯甲基)-1H-咪唑并l-4-基]乙酮

  • 69196-02-7

    3-(2-deoxy-3,5-di-O-p-toluoyl-α-D-erythro-pentofuranosyl)-6,7-dihydroimidazo[4,5-d][1,3]diazepin-8(3H)-one

  • 69195-92-2

    2-氨基-1-(5-氨基-1H-咪唑-4-基)乙酮双盐酸盐

立即下载安装“化学加”APP
专业、功能强大，随时调用更加方便
下载APP